Last reviewed · How we verify
TACROLIMUS ANHYDROUS
TACROLIMUS ANHYDROUS is a drug. It is currently FDA-approved (first approved 1994).
Tacrolimus anhydrous is a small molecule inhibitor of the FK506-binding protein 1A, which is involved in the immune response. It has been studied as a treatment for various conditions, including Focal Segmental Glomerulosclerosis, Oral Lichen Planus, Diabetes Mellitus, Type 1, Severe Sickle Cell Disease, and Bone Marrow Failure Syndromes.
At a glance
| Generic name | TACROLIMUS ANHYDROUS |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 1994 |
Approved indications
Common side effects
Key clinical trials
- Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia (PHASE2)
- Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita (PHASE2)
- Tocilizumab in Lung Transplantation (PHASE2)
- Use of Belatacept to Delay Tacrolimus Initiation in Kidney Transplant Patients With Delayed Graft Function
- A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation (PHASE2, PHASE3)
- Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases (PHASE1, PHASE2)
- MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases (PHASE2)
- Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TACROLIMUS ANHYDROUS CI brief — competitive landscape report
- TACROLIMUS ANHYDROUS updates RSS · CI watch RSS
Frequently asked questions about TACROLIMUS ANHYDROUS
What is TACROLIMUS ANHYDROUS?
When was TACROLIMUS ANHYDROUS approved?
What development phase is TACROLIMUS ANHYDROUS in?
Related
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing